Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

The efficacy and safety of combining bevacizumab (7.5 and 15 mg/kg) with docetaxel as first-line therapy for human epidermal growth factor receptor 2 (HER2) -negative, locally recurrent or metastatic breast cancer (MBC) was investigated in a three-arm, placebo-controlled, phase III trial. Patients (...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology Jg. 28; H. 20; S. 3239
Hauptverfasser:	Miles, David W, Chan, Arlene, Dirix, Luc Y, Cortés, Javier, Pivot, Xavier, Tomczak, Piotr, Delozier, Thierry, Sohn, Joo Hyuk, Provencher, Louise, Puglisi, Fabio, Harbeck, Nadia, Steger, Guenther G, Schneeweiss, Andreas, Wardley, Andrew M, Chlistalla, Andreas, Romieu, Gilles
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 10.07.2010
Schlagworte:	Adult Aged Aged, 80 and over Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Breast Neoplasms - pathology Drug Administration Schedule Female Humans Middle Aged Neoplasm Metastasis Neoplasm Recurrence, Local - drug therapy Placebos - administration & dosage Receptor, Epidermal Growth Factor - metabolism Taxoids - administration & dosage
ISSN:	1527-7755, 1527-7755
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!